Shares of World Wrestling Entertainment, Inc. (NYSE: WWE) rose after news of Endeavor Group Holdings, Inc (NYSE: EDR)'s plans to merge its UFC subsidiary with WWE and
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy peers.